Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2024-10-22
Product name:
JAMPLYTE + BISACODYL
DIN:
02552612
Product Monograph/Veterinary Labelling:
Date:
2024-10-22
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
JAMP PHARMA CORPORATION
1310 Rue Nobel
Boucherville
Quebec
Canada
J4B 5H3
Class:
Human
Dosage form(s):
Tablet (Delayed-Release) , Kit , Powder For Solution
Route(s) of administration:
Oral
Number of active ingredient(s):
6
Schedule(s):
Ethical
American Hospital Formulary Service (AHFS): See footnote 3
56:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
A06AB52 BISACODYL, COMBINATIONS
Active ingredient group (AIG) number:See footnote5
0652579002
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| BISACODYL | 5 MG / TAB |
| POLYETHYLENE GLYCOL 3350 | 59.55 G / SACHET |
| POTASSIUM CHLORIDE | 0.76 G / SACHET |
| SODIUM BICARBONATE | 1.69 G / SACHET |
| SODIUM CHLORIDE | 1.46 G / SACHET |
| SODIUM SULFATE | 5.74 G / SACHET |